Drug Trial Radar · NCT02951754
Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder
Last checked: Nov 19, 2026Latest source record: Nov 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Feb 2002
Primary completion
Dec 2032
Study completion Dec 2032
Sponsor
- Lead sponsor
- Hospital de Clinicas de Porto AlegreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Federal University of Rio Grande do Sul; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Coordination for the Improvement of Higher Education Personnel
- First posted
- Nov 1, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.
Conditions
- Attention Deficit Disorder With Hyperactivity
Interventions
Immediate-release MethylphenidateDrug
Standard initial dose of 10 mg, twice or three times daily with doses increasing weekly until symptom control or occurrence of limiting adverse effects
Primary outcomes
What the sponsor says the trial is designed to measure.
- Self-reported changes in severity of ADHD symptomsTime frame: 1yr
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Program on Attention-Deficit/Hyperactivity Disorder (PRODAH); Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.